Guideline-Practice Gap in the Management of Predialysis Chronic Kidney Disease Mineral Bone Disorder in Japan

Therapeutic Apheresis and Dialysis

Volumn 15, Issue SUPPL.1, 2011, Pages 2-8

  Hamano, Takayuki ^a   Fujii, Naohiko ^d   Matsui, Isao ^a   Nakano, Chikako ^a   Inoue, Kazunori ^a   Tomida, Kodo ^e   Mikami, Satoshi ^b   Okada, Noriyuki ^c   Tsubakihara, Yoshiharu ^c   Rakugi, Hiromi ^a   Isaka, Yoshitaka ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Higashi Kohri Hospital   (Japan)

^c OSAKA GENERAL MEDICAL CENTER   (Japan)

^d Hyogo Prefectural Nishinomiya Hospital   (Japan)

^e KANSAI ROSAI HOSPITAL   (Japan)

Author keywords

25 hydroxyvitamin D; Active vitamin D; Chronic kidney disease mineral bone disorder; Diabetes mellitus; Proteinuria; Secondary hyperparathyroidism

Indexed keywords

25 HYDROXYVITAMIN D; ALFACALCIDOL; CALCITRIOL; COLECALCIFEROL; ERGOCALCIFEROL; VITAMIN D;

ADULT; AGED; ARTICLE; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; FEMALE; HEMODIALYSIS; HUMAN; HYPERPARATHYROIDISM; HYPOPHOSPHATEMIA; JAPAN; MAJOR CLINICAL STUDY; MALE; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN RESTRICTION; PROTEIN URINE LEVEL; PROTEINURIA; RENAL OSTEODYSTROPHY; SECONDARY HYPERPARATHYROIDISM; SEX DIFFERENCE; STAGING; VITAMIN D DEFICIENCY;

AGED; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES, METABOLIC; CALCITRIOL; CHRONIC DISEASE; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS; FEMALE; HUMANS; HYDROXYCHOLECALCIFEROLS; HYPERPARATHYROIDISM, SECONDARY; JAPAN; KIDNEY DISEASES; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; PROTEINURIA; RISK FACTORS; SEX FACTORS; VITAMIN D;

EID: 79956222032     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2011.00918.x     Document Type: Article

References (29)

1. Nakai S, Akiba T, Kazama J etal. Effects of serum calcium, phosphorous, and intact parathyroid hormone levels on survival in chronic hemodialysis patients in Japan. Ther Apher Dial 2008;12:49-54.
2. Levin A, Djurdjev O, Beaulieu M, Er L. Variability and risk factors for kidney disease progression and death following attainment of stage 4 CKD in a referred cohort. Am J Kidney Dis 2008;52:661-71.
3. Norris KC, Greene T, Kopple J etal. Baseline predictors of renal disease progression in the African American Study of Hypertension and Kidney Disease. J Am Soc Nephrol 2006;17:2928-36.
4. Kovesdy CP, Ahmadzadeh S, Anderson JE, Kalantar-Zadeh K. Secondary hyperparathyroidism is associated with higher mortality in men with moderate to severe chronic kidney disease. Kidney Int 2008;73:1296-302.
5. Schwarz S, Trivedi BK, Kalantar-Zadeh K, Kovesdy CP. Association of disorders in mineral metabolism with progression of chronic kidney disease. Clin J Am Soc Nephrol 2006;1:825-31.
6. Kovesdy CP, Ahmadzadeh S, Anderson JE, Kalantar-Zadeh K. Association of activated vitamin D treatment and mortality in chronic kidney disease. Arch Intern Med 2008;168:397-403.
7. KDOQI. Clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003;42:S1-201.
8. Kidney Disease: Improving Global Outcomes. KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009;76:S1-130.
9. Tanaka H, Hamano T, Fujii N etal. The impact of diabetes mellitus on vitamin D metabolism in predialysis patients. Bone 2009;45:949-55.
10. Matsuo S, Imai E, Horio M etal. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009;53:982-92.
11. Tentori F, Blayney MJ, Albert JM etal. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2008;52:519-30.
12. Kazama JJ. Japanese Society of Dialysis Therapy treatment guidelines for secondary hyperparathyroidism. Ther Apher Dial 2007;11(Suppl 1):S44-47.
13. Levin A, Bakris GL, Molitch M etal. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007;71:31-8.
14. McKinney K, Breitkopf CR, Berenson AB. Association of race, body fat and season with vitamin D status among young women: a cross-sectional study. Clin Endocrinol (Oxf) 2008;69:535-41.
15. Kosmadakis G, Duja S, Basta M, Iqbal J, Warwick G, Medcalf JF. 25(OH) vitamin D deficiency among SE Asians and Caucasians with CKD 3 and 4, and its role in hyperparathyroidism. Kidney Int 2008;73:360. author reply 360-361.
16. Imai E, Matsuo S, Makino H etal. Chronic Kidney Disease Japan Cohort study: baseline characteristics and factors associated with causative diseases and renal function. Clin Exp Nephrol 2010;14:558-70.
17. Lash JP, Go AS, Appel LJ etal. Chronic Renal Insufficiency Cohort (CRIC) Study: baseline characteristics and associations with kidney function. Clin J Am Soc Nephrol 2009;4:1302-11.
18. Kriz W, Gretz N, Lemley KV. Progression of glomerular diseases: is the podocyte the culprit? Kidney Int 1998;54:687-97.
19. Matsusaka T, Xin J, Niwa S etal. Genetic engineering of glomerular sclerosis in the mouse via control of onset and severity of podocyte-specific injury. J Am Soc Nephrol 2005;16:1013-23.
20. Matsui I, Hamano T, Tomida K etal. Active vitamin D and its analogue, 22-oxacalcitriol, ameliorate puromycin aminonucleoside-induced nephrosis in rats. Nephrol Dial Transplant 2009;24:2354-61.
21. Safadi FF, Thornton P, Magiera H etal. Osteopathy and resistance to vitamin D toxicity in mice null for vitamin D binding protein. J Clin Invest 1999;103:239-51.
22. Kriz W. Podocyte is the major culprit accounting for the progression of chronic renal disease. Microsc Res Tech 2002;57:189-95.
23. Nakajima H, Takenaka M, Kaimori JY etal. Activation of the signal transducer and activator of transcription signaling pathway in renal proximal tubular cells by albumin. J Am Soc Nephrol 2004;15:276-85.
24. Crivello JF. Oxidative stress limits vitamin D metabolism by bovine proximal tubule cells in vitro. Arch Biochem Biophys 1988;262:471-80.
25. Fishbane S, Chittineni H, Packman M, Dutka P, Ali N, Durie N. Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial. Am J Kidney Dis 2009;54:647-52.
26. de Zeeuw D, Agarwal R, Amdahl M etal. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet 2010;376:1543-51.
27. Deb DK, Sun T, Wong KE etal. Combined vitamin D analog and AT1 receptor antagonist synergistically block the development of kidney disease in a model of type 2 diabetes. Kidney Int 2010;77:1000-9.
28. Mizobuchi M, Morrissey J, Finch JL etal. Combination therapy with an angiotensin-converting enzyme inhibitor and a vitamin D analog suppresses the progression of renal insufficiency in uremic rats. J Am Soc Nephrol 2007;18:1796-806.
29. Slatopolsky E, Dusso A, Brown A. New analogs of vitamin D3. Kidney Int Suppl 1999;73:S46-51.